Emergent BioSolutions Inc.
EBS
$5.63
-$0.25-4.25%
NYSE
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 14.12% | -33.73% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 14.12% | -33.73% | |||
| Cost of Revenue | 76.63% | -55.09% | |||
| Gross Profit | -12.53% | -16.87% | |||
| SG&A Expenses | -13.18% | -20.03% | |||
| Depreciation & Amortization | 0.00% | 0.00% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -13.67% | -10.28% | |||
| Operating Income | 1,272.09% | -105.97% | |||
| Income Before Tax | 435.87% | -119.38% | |||
| Income Tax Expenses | 567.57% | -86.59% | |||
| Earnings from Continuing Operations | 317.25% | -127.26% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 317.25% | -127.26% | |||
| EBIT | 1,272.09% | -105.97% | |||
| EBITDA | 258.10% | -78.51% | |||
| EPS Basic | 316.45% | -126.71% | |||
| Normalized Basic EPS | 545.58% | -124.95% | |||
| EPS Diluted | 305.28% | -128.14% | |||
| Normalized Diluted EPS | 523.03% | -126.13% | |||
| Average Basic Shares Outstanding | 0.37% | 2.07% | |||
| Average Diluted Shares Outstanding | 5.72% | -2.52% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||